Crispr Therapeutics (CRSP) makes catapulted higher Monday after biotechnology announced that it dosed a patient with its CRISPR gene editing treatment – making it the first company to use the technology in a clinical study.
X  On the stock market today, the Crispr share rose 25.2% to 39.65. Parts of their partner, Vertex Pharmaceuticals (VRTX), rose a fraction.
The patient received CTX001, a CRISPR gene editing treatment that was tested in beta-thalassemia in Europe. Crispr and Vertex also test CTX001 in the US in patients with sickle cell disease. The first patient in that study will receive the CRISPR gene editing treatment by mid-2019. "We have made tremendous progress with CTX001," said Crispr CEO Samarth Kulkarni in a written statement.
] Get exclusive IBD analysis and action news daily.
 Sign up now!
Get exclusive IBD analysis and action news daily.
Please enter a valid email address
Please select a newsletter
You will now receive the IBD newsletter
Something went wrong!
Contact customer service
The news sent other biotech stocks popping. Editas Medicine (EDIT) and Intellia Therapeutics (NTLA) shares increased by 5.3% and 6.1% respectively at the end. Both biotech companies are working on CRISPR gene editing therapies.
YOU CAN NEVER LIKE:
Top 5 Biotech shares face growth challenges – is there anything immune?
What pharmaceutical stocks are Over all other shares?
Danaher to buy GE Biopharma Segment in $ 21.4 billion Takeover